Biotech

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio Clementia’s late-stage drug candidate, palovarotene, has rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder and a path to approval in 2020 Acquisi ...

Cyclicals and Biotechs are Trading Above Their 200-Day Lines

Editor's Note: This article was originally published in John Murphy's Market Message on Thursday, January 31st at 12:34pm ET. Chart 4 shows the Consumer Discretionary SPDR (XLY) trading above its 200-day line in today's trading. That a positive sign for the economically-sensitive sector and th ...

The Science of Commercialization

November 8, 2018; Hamilton, Ontario, Canada; Triumvira is a company started by Dr. Jonathan Bramson, associate dean of research for the Faculty of Health Sciences, McMaster University, along with colleagues Chris Helsen and Danielle Hayes. Photo by Ron Scheffler for McMaster University. This arti ...

Q4 2018 Share Price Performance

Analysis: Stocks Get Hammered  In this blog post, the Bloom Burton equity research team summarizes the performance of the Canadian healthcare sector during 4Q-2018, and provides commentary on select stock movements and overall market trends. Inclusion Criteria Our analysis includes all Canadian ...

Zymeworks stock is a buy, Paradigm Capital says

Clinical-stage biopharmaceutical company Zymeworks (Zymeworks Stock Quote, Chart TSX, NYSE:ZYME) reported on Monday that Eli Lilly, one of ZYME’s pharma partners, has filed an investigational new drug (IND) submission for one of its ZYME-partnered immuno-oncology antibodies, an event which shows ...

New deal for Knight Therapeutics doesn’t move the needle, says Mackie Research

Commercial-stage specialty pharma company Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD) has entered into a licensing agreement with Puma Biotechnology for the exclusive right to commercialize Puma’s cancer drug Nerlynx (neratinib) in Canada. The deal moves up GUD’s top an ...

The biotech sector is undervalued, John Zechner says

If you’re looking for a market sector that should do well in 2019, then biotechnology should be on your list, says John Zechner, who prefers Celgene (Celgene Stock Quote, Chart NASDAQ:CELG) over Gilead Sciences (Gilead Sciences Stock Quote, Chart NASDAQ:GILD) and likes the Nasdaq Biotechnology ET ...

Multiple Big Name Pharma Stocks Help Remedy The Pain

Pharmaceutical stocks were a standout in November. The big global names had an exceptional month. While they are categorized as defensive stocks, these heavyweights have very powerful biotechnology investments. The pharmaceutical stocks listed below all hit new highs within November. While the $SPX ...

ProMetic Life Sciences still has financial risk, Echelon Wealth Partners says

Biopharm company ProMetic Life Sciences (ProMetic Life Sciences Stock Quote, Chart TSX:PLI) announced its third quarter 2018 financials this week, but the focus remains on ProMetic making regulatory progress with its therapeutic protein Ryplazim (plasminogen), says analyst Douglas Loe of Echelon We ...

America’s Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub

America’s Midwestern Gem: How Chicago is Building the Next Biomedical Research Hub By Matthew Johnson Kapoor, Anish. Cloud Gate. 2006. Chicago. – photograph by Matthew Johnson, 2018 In his latest post, Matthew Johnson takes us to Chicago – America’s “Windy City.” Known as a printing and ...